Quick jump to page content
  • Main Navigation
  • Main Content
  • Sidebar
  • Register
  • Login
##common.pageHeaderLogo.altText##
  • Home
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Current
  • Archives
  • Submission

Search

Advanced filters

Search Results

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

Diamant Thaci, Kenneth Gordon , Melinda Gooderham, Bruce Strober , Neil Korman, Subhashis Banerjee, Subhashis Banerjee, Elizabeth Colston, Jonghyeon Kim, John Throup, Akimichi Morita

Page s37

Poster PDF
1 - 1 of 1 items

 

 

 

 

180x77

Make a Submission

SKIN is a bi-monthly, peer-reviewed, online medical journal dedicated to providing an enhanced route to disseminate new dermatologic knowledge on all aspects of cutaneous disease. The Journal is Open Access. ISSN: 2574-1624

Important Links

  • About the Journal
  • Editorial Team
  • Submissions
  • Contact

Contact

  • Email: jofskin@gmail.com
  • Website: www.jofskin.org
  • Mailing Address: PO Box 569 Millwood NY 10546
OJS Hosting, Support, and Customization by: OpenJournalSystems.com

Modal Header